12/17/2023 0 Comments Stem cell treatment for neuropathyMoreover, stem cell treatment does not always exert positive results in SCI- induced chronic pain (e.g. However, it is interesting to point out that peripheral neuropathic pain seems to be more responsive to stem cell therapy than SCI- induced chronic pain. Stem cell transplantation can effectively relieve neuropathic pain under different pathological conditions. Stem cell researches should focus on both experimental and clinical studies of neuropathic pain in the future. Summary: The analgesic effect of stem cells depends on the capacity to offer a multipotent cellular source for replacing injured neural cells and delivering trophic factors to lesion sites. aggravating pain above the lesion spinal cord segment). Moreover, stem cell treatment does not always exert positive results in SCI-induced chronic pain (e.g. However, it is interesting to point out that peripheral neuropathic pain seems to be more responsive to stem cell therapy than SCI-induced chronic pain. Accumulating evidence has shown that stem cell transplantation has a therapeutic effect on neuropathic pain. Recent findings: Recently, the successful use of stem cell for the treatment of a diverse spectrum of diseases in animals has attracted more attentions from pain scientists. Method: We reviewed recent articles and literatures about stem cells for the treatment of neuropathic pain, in order to identify the types of stem cells, delivery approaches and the advances of stem cells for the treatment of peripheral nerve injury induced neuropathic pain, painful diabetic peripheral neuropathy and spinal cord injury (SCI) induced chronic pain. This article aimed to review important and illustrative results from recent stem cell studies under various neuropathic pain conditions and to interpret their clinical implications for stem cell transplantation. Stem cell transplantation may be an important approach for the treatment of neuropathic pain. Despite multiple therapeutic strategies, the medical community still faces a challenge to treat neuropathic pain in a complete and definitive way, since the pathogenesis of this hypersensitive state is very complex. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment.Aim of review: Neuropathic pain induced by injury to the somatosensory system is a great clinical problem. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. Type-1 Diabetes is generally treated with exogenous insulin administration.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |